Why is retatrutide administered once a week?

Why Retatrutide is Administered Once Weekly

Retatrutide is administered once weekly because its pharmacokinetic profile, with a mean half-life of approximately 6 days, supports this convenient dosing schedule while maintaining therapeutic drug levels throughout the week. 1

Pharmacokinetic Rationale

The once-weekly dosing of retatrutide is fundamentally driven by its favorable pharmacokinetic properties:

• The drug demonstrates dose-proportional pharmacokinetics with a mean half-life of approximately 6 days, which is sufficiently long to maintain therapeutic concentrations between weekly doses 1
• This extended half-life allows for steady-state drug levels to be achieved and maintained with weekly subcutaneous administration 2
• The pharmacokinetic profile was established through Phase 1 and Phase 2 clinical trials, which confirmed that once-weekly dosing provides consistent drug exposure 1

Clinical Trial Evidence

The once-weekly dosing regimen has been validated across multiple clinical trials:

• Phase 2 trials demonstrated that subcutaneous retatrutide administered once weekly resulted in substantial weight reductions, with the 12 mg dose achieving a mean 24.2% weight loss at 48 weeks compared to 2.1% with placebo 3
• The dosing schedule proved effective across different dose levels (1 mg, 4 mg, 8 mg, and 12 mg), all administered once weekly 3
• In adults with type 2 diabetes, once-weekly retatrutide treatment for 36 weeks demonstrated significant improvements in appetite control and eating behaviors, supporting the adequacy of weekly dosing for sustained therapeutic effects 4

Practical Advantages

The once-weekly schedule offers several clinical benefits:

• Weekly dosing enhances patient convenience and adherence, particularly important for chronic obesity management where long-term treatment is required 2
• This dosing frequency aligns with other successful incretin-based therapies that have established weekly administration as an effective standard 1
• The subcutaneous route combined with weekly dosing makes the medication suitable for self-administration, improving accessibility 2

Safety Profile with Weekly Dosing

The once-weekly regimen has demonstrated an acceptable safety profile:

• The most common adverse events were gastrointestinal in nature, dose-related, and mostly mild to moderate in severity 3
• These side effects were partially mitigated by using lower starting doses (2 mg versus 4 mg) before escalating 3
• The weekly dosing schedule allows for appropriate dose titration to balance efficacy with tolerability 1